Nifedipine gastrointestinal therapeutic system (GITS) in the treatment of coronary heart disease and hypertension

References

• Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation92, 1326–1331 (1995).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J. Am. Med. Assoc.274(8), 620–625 (1995).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356(9227), 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Lubsen J, Kirwan BA et al.; A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet364(9437), 849–857 (2004).
   PubMed Web of Science ®Google Scholar
• Sorkin EM, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs30(3), 182–274 (1985).
   PubMed Web of Science ®Google Scholar
• Murdoch D, Brogden RN. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs41(5), 737–779 (1991).
   PubMed Web of Science ®Google Scholar
• Brogden RN, McTavish D. Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs50(3), 495–512 (1995).
   PubMed Web of Science ®Google Scholar
• Croom KF, Wellington K. Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Drugs66, 497–528 (2006).
   PubMed Web of Science ®Google Scholar
• Van Zwieten PA. Hydrogen sulphide: not only foul smelling, but also pathophysiologically relevant. J. Hypertens.21, 1819–1820 (2003).
   PubMed Web of Science ®Google Scholar
• Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J. Hypertens.22, 1641–1648 (2004).
   PubMed Web of Science ®Google Scholar
• Van Zwieten PA, Dunselman PHJM. Zijn retard preparaten uitwisselbaar? Cardio. Actueel 9/14 (2004).
   Google Scholar
• Wonnemann M, Schug B, Schmucker K, Brendel E, van Zwieten P, Blume H. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. Int. J. Clin. Pharmacol. Ther.44(1), 38–48 (2006).
   PubMed Web of Science ®Google Scholar
• Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am. J. Med.83(6B), 10–14 (1987).
   PubMedGoogle Scholar
• Lubsen J, Voko Z, Poole-Wilson PA, Kirwan B-A, de Brouwer S; on behalf of the ACTION investigators. Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. J. Clin. Epidemiol. (2007) (In press).
   Google Scholar
• Hilleman DE, Mohiuddin SM, Lucas BD Jr, Shinn B, Elsasser GN. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension. Clin. Ther.15, 1002–1010 (1993).
   PubMed Web of Science ®Google Scholar
• Glaser JP et al. The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study Group. Clin. Ther.17, 296–312 (1995).
   PubMed Web of Science ®Google Scholar
• Simon A, Levenson J. Clinical use of nifedipine GITS in the treatment of hypertension: an overview. Expert Opin. Pharmacother.4(1), 95–106 (2003).
   PubMed Web of Science ®Google Scholar
• Kloner RA. Nifedipine in ischemic heart disease. Circulation92(5), 1074–1078 (1995).
   PubMed Web of Science ®Google Scholar
• Siu SC, Jacoby R, Phillips RT, Nesto RW. Comparative efficacy of nifedipine gastrointestinal therapeutic system versus diltiazem when added to β-blockers in stable angina pectoris. Am. J. Cardiol.71, 887–892 (1993).
   PubMed Web of Science ®Google Scholar
• Zanolla L, Franceschini L, Rossi L, Ochan M, Amigoni S, Zardini P. Nifedipine GITS versus diltiazem in chronic stable angina: a randomised multicentre study. Br. J. Clin. Pract.88(Suppl.), 27–35 (1997).
   Google Scholar
• De Vries RJ, VandenHeuvel AF, Lok DJ et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. Int. J Cardiol.57(2), 143–150 (1996).
   PubMed Web of Science ®Google Scholar
• Walker JM, Curry PVL, Bailey AE, Steare SE. A comparison of nifedipine (LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Int. J. Cardiol.53, 117–126 (1996).
   PubMed Web of Science ®Google Scholar
• Parmley WW, Nesto R, Singh BN, Deanfield J, Gottlieb SO. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J. Am. Coll. Cardiol.19, 1380–1389 (1992).
   PubMed Web of Science ®Google Scholar
• Toal CB, Motro M, Baird MG et al. Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina. Can. J. Cardiol.15, 1103–1109 (1999).
   PubMed Web of Science ®Google Scholar
• Lubsen J, Poole-Wilson PA, Pocock SJ et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic System. Eur. Heart J.19(Suppl. I), I20–I32 (1998).
   PubMed Web of Science ®Google Scholar
• Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J. Hypertens.23(3), 641–648 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J. Am. Med. Assoc.292(18), 2217–2225 (2004).
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Leoncini G, Parodi A. Use of nifedipine in the treatment of hypertension. Expert Rev. Cardiovasc. Ther.3(1), 43–50 (2005).
   PubMedGoogle Scholar
• Mancia G, Brown M, Castaigne A et al.; INSIGHT. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension41(3), 431–436 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, Omboni S, Parati G, on behalf of the INSIGHT investigators. Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). J. Hypertens.20, 545–553 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, Ruilope L, Palmer C et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension – a subanalysis of the INSIGHT study. Blood Press.13(5), 310–315 (2004).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet363(9426), 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Fagard RH, Staessen JA, Thijs L et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation102(10), 1079–1081 (2000).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Takeuchi M. Atheroprotective properties of nifedipine. Int. J.2, 63–67 (2005).
   Web of Science ®Google Scholar
• Motro M, Shemesh J. Calcium channel blocker nifedipine slow down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension37, 1410–1413 (2001).
   PubMed Web of Science ®Google Scholar
• Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation103, 2949–2954 (2001).
   PubMed Web of Science ®Google Scholar
• Luscher TF, Azancot I, Balbi M, Bonnier JJRM et al. “Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I study (evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function). Circulation107, 422–428 (2003).
   PubMed Web of Science ®Google Scholar
• Schellekens S, Verheugt FWA. Hotline sessions of the 26th European Congress of Cardiology. Eur. Heart J.25, 2164–2166 (2004).
   PubMedGoogle Scholar
• Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet356(9246), 1955–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362(9395), 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am. J. Hypertens.17(9), 817–822 (2004).
   PubMed Web of Science ®Google Scholar
• De Leeuw PW, Ruilope LM, Palmer CR et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch. Intern. Med.164(22), 2459–2464 (2004).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Kirwan B-A, Voko Z et al.; on behalf of the ACTION investigators. Resource utilization implications of treatment can be assessed when clinical trial data are reported appropriately. J. Clin. Epidemiol. (2007) (In press).
   Google Scholar